Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Expected to Earn Q1 2024 Earnings of ($0.61) Per Share

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Investment analysts at Leerink Partnrs boosted their Q1 2024 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a note issued to investors on Monday, April 15th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will post earnings of ($0.61) per share for the quarter, up from their previous estimate of ($0.64). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.37) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.65 EPS.

A number of other research firms have also recently commented on MRNS. Truist Financial reduced their price objective on Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. Royal Bank of Canada reissued a “sector perform” rating and set a $3.00 price target (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday. StockNews.com lowered Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Robert W. Baird reissued a “neutral” rating on shares of Marinus Pharmaceuticals in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Marinus Pharmaceuticals in a research note on Tuesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Marinus Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $16.07.

Marinus Pharmaceuticals Stock Down 2.1 %

Marinus Pharmaceuticals stock opened at $1.41 on Thursday. The stock has a market cap of $77.45 million, a PE ratio of -0.54 and a beta of 0.91. The company has a debt-to-equity ratio of 5.68, a quick ratio of 4.01 and a current ratio of 4.07. Marinus Pharmaceuticals has a one year low of $1.11 and a one year high of $11.26. The stock has a fifty day moving average of $8.55 and a 200 day moving average of $8.40.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The business had revenue of $7.19 million during the quarter, compared to analysts’ expectations of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same quarter in the prior year, the firm earned ($0.76) EPS.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Marinus Pharmaceuticals by 1.2% during the third quarter. Vanguard Group Inc. now owns 2,577,475 shares of the biopharmaceutical company’s stock valued at $20,749,000 after buying an additional 31,233 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Marinus Pharmaceuticals by 69.5% during the third quarter. Schonfeld Strategic Advisors LLC now owns 253,412 shares of the biopharmaceutical company’s stock valued at $2,040,000 after buying an additional 103,935 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in Marinus Pharmaceuticals by 6.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,904,476 shares of the biopharmaceutical company’s stock valued at $23,381,000 after buying an additional 173,226 shares during the last quarter. Jennison Associates LLC raised its position in Marinus Pharmaceuticals by 58.4% during the third quarter. Jennison Associates LLC now owns 2,955,343 shares of the biopharmaceutical company’s stock valued at $23,791,000 after purchasing an additional 1,089,913 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in Marinus Pharmaceuticals during the fourth quarter valued at approximately $134,000. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.